Merck Serono will continue developing the cancer treatment tecemotide, which is licensed from Oncothyreon Inc. (Nasdaq: ONTY). Shares of Oncothyreon soared 43 cents to $2.23.
Development Continues For Oncothyreon’s Tecemotide
September 25, 2013 at 06:38 AM EDT
